The sustained efficacy and safety data through two years strengthen the case for regulatory submission in achondroplasia. Monitor for upcoming FDA/EMA filing announcements and potential partnership or commercialization updates. The stock may see positive momentum as the data derisk the program.
Price Chart
Executive Summary
Ascendis Pharma announced Week 104 radiographic data from the pivotal ApproaCH trial of TransCon CNP (navepegritide) in achondroplasia, showing continued improvements in lower extremity alignment (tibial-femoral angle) through two years with a favorable safety profile. The data reinforce the drug's disease-modifying potential and support regulatory advancement.
Key Facts
- TransCon CNP-treated children showed mean TFA improvement of -2.2 degrees over two years (baseline 9.1° to 6.9° at Week 104).
- In children with baseline TFA ≥5° (genu varum), mean TFA improved -3.8 degrees over two years (13.4° to 9.6°).
- Placebo-switch group showed TFA improvement of -1.7 degrees during the 52-week open-label extension.
- Mean TFA Z-score decreased from 3.62 at baseline to 2.96 at Week 104 in the continuous-treatment group.
- No symptomatic hypotension, no acceleration of bone age, and no treatment discontinuations due to adverse events.
- Data presented at the 12th International Conference on Children's Bone Health (ICCBH 2026) in Montreal.
Financial Impact
No financial data in filing; positive clinical data supports TransCon CNP's regulatory and commercial prospects in achondroplasia, a market with limited approved therapies.
Risk Factors
- Competition from BioMarin's Voxzogo (vosoritide) already approved for achondroplasia.
- Regulatory timelines and potential requirements for additional clinical data.
- Commercial adoption dependent on pricing, reimbursement, and physician preference.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-290485 |
| Document: 0001193125-26-290485-index-headers.html | 0001193125-26-290485 |
| Document: 0001193125-26-290485-index.html | 0001193125-26-290485 |
| Document: 0001193125-26-290485.txt | 0001193125-26-290485 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access